Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors

Int J Dermatol. 2024 Dec 30. doi: 10.1111/ijd.17630. Online ahead of print.

Authors

Ioannis-Alexios Koumprentziotis¹, Natalia Rompoti¹, Irene Stefanaki¹, Charitomeni Vavouli¹, Maria Politou¹, Marina Papoutsaki¹, Alexander Stratigos¹, Electra Nicolaidou¹

Affiliation

¹ 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.

PMID: 39740018
DOI: 10.1111/ijd.17630

No abstract available

Keywords: bimekizumab; biologics; interleukin‐17; intra‐class switch; psoriasis.